Stay updated on Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.

Latest updates to the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated to reflect the latest results and details of a study investigating Sacituzumab Govitecan for metastatic castration-resistant prostate cancer, including new reporting dates and specific eligibility criteria for participants.SummaryDifference7%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed study descriptions and eligibility criteria for a clinical trial on Sacituzumab Govitecan for prostate cancer, while adding new identifiers and collaborators.SummaryDifference42%
- Check30 days agoChange DetectedThe page has been updated to reflect the submission of results and has been revised to version 2.14.4.SummaryDifference0.2%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.